Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
China RUBY: dostarlimab plus carboplatin-paclitaxel followed by dostarlimab in dMMR/MSI-H advanced or recurrent endometrial cancer
CTR20253666Phase 2Active
- Sponsor
- GSK
- Start
- Dec 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab, carboplatin, paclitaxel in endometrial cancer (EC), sponsored by GSK. Started Dec 2025; status: active.
02
Drugs
dostarlimabcarboplatinpaclitaxel
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20253666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253666.